PMBS Stock UPDATES Puramed Bioscience (PMBS) 0.0002 08/05/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Puramed Bioscience (PMBS) 0.0002 $PMBS

PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M
PR Newswire - Wed Jul 30, 12:57PM CDT
PuraMed BioScience®, Inc., (OTCPink MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is rebranding the LipiGesic® M name along with the name's red and yellow logo. The former will be replaced with the trademarked name MigraPure® going forward. The new name, logo, and color palette of PuraMed's homeopathic, natural migraine pain reliever will be reintroduced into selected segments of the retail marketplace.

PuraMed BioScience forms corporate sponsor partnership with Operation Troop Aid for US military
M2 - Wed Jul 23, 7:38AM CDT
Healthcare company PuraMed BioScience (PNK MBS) reported on Tuesday the launch of a corporate sponsor agreement with Operation Troop Aid in aid of the US military.

PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages
PR Newswire - Tue Jul 22, 7:49AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is a corporate sponsor of Operation Troop Aid.

PuraMed BioScience Announces Product Donation at a Sponsorship Level to Operation Gratitude
PR Newswire - Tue Jul 08, 8:11AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is now a corporate sponsor of Operation Gratitude.

PuraMed BioScience and Honoring Our Troops Partner Together to Sponsor a PTSD Event
PR Newswire - Wed Jun 11, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that in conjunction with Migraine Awareness month, the company sponsored the San Diego Operation Engage America event with Honoring Our Troops on Saturday, June 7, 2014. PuraMed provided samples of LipiGesic® M along with educational information for veterans, which was distributed at the Honoring Our Troops booth.

PuraMed BioScience elects Patricia McMurtrie as COO
M2 - Wed Jun 04, 7:21AM CDT
Medicinal company PuraMed BioScience (PMBS:OTCBB) stated on Tuesday that Patricia McMurtrie has been named as its chief operating officer, president and director.

PuraMed BioScience Announces Appointment of Patricia McMurtrie as Chief Operating Officer
PR Newswire - Tue Jun 03, 2:19PM CDT
PuraMed BioScience®, Inc., (PMBS: OTCBB), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that Patricia McMurtrie will hold the positions of COO, President, and Director, effective May 27, 2014. In this role, Ms. McMurtrie will be responsible for the oversight of day-to-day business functions as well as key product development and distribution functions.

PuraMed BioScience Explores the Development of Hemp and THC-Free Cannabis Formulations to Expand Its Product Line
PRWeb - Mon Mar 24, 6:09AM CDT
PuraMed BioScience(R), Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that it is seriously exploring the development of cannabinoid and hemp-based formulations to expand its natural and homeopathic product line.

Energy Utilities Focus on Providing Reliable and Safe Service while Meeting Compliance Standards
PR Newswire - Wed Feb 26, 7:00AM CST
To streamline and standardize gas compliance processes and adapt to the demands of the energy service and delivery industry, Ameren Corporation has turned to the mobile workforce management market leader, ClickSoftware Technologies Ltd. (NasdaqGS: CKSW). The implementation of ClickSoftware's scheduling and mobility offering for gas compliance processes will eliminate paper inspection forms and improve data quality, improve flexibility to adapt to rapidly changing regulatory requirements, and provide management with greater visibility into compliance activities.

Merger Approval, Financial Results, Conference Call Schedule, and Stock Price Updates - Research Report on Omnicom, Global Payments, FleetCor, Interpublic, and Fiserv
PR Newswire - Wed Jan 15, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
PR Newswire - Thu Aug 29, 11:03AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
PR Newswire - Thu Aug 22, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it will sponsor the 5th Miles for Migraine Race San Francisco by supplying $5,000 of LipiGesic M for the participants.

PuraMed BioScience Inc signs LipiGesic M distributor agreement with OuterBanks Outdoors
M2 - Thu Aug 15, 10:13AM CDT
Healthcare company PuraMed BioScience Inc (OTC BB MBS) reported on Wednesday the launch of an exclusive distribution agreement to sell LipiGesic M on Amazon.com..

PuraMed BioScience Announces Distributor Agreement with OuterBanks Outdoors
PR Newswire - Wed Aug 14, 1:08PM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that it has entered into an exclusive distribution agreement with OuterBanks Outdoors to sell LipiGesic® M, its homeopathic formulation of feverfew and ginger for treatment of acute migraine, on Amazon.com.

LipiGesic M is the only recommended first-line therapy for acute migraine that has no evidence of rebound headache
PR Newswire - Mon Aug 05, 2:44PM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, confirmed today that its product, LipiGesic® M, a homeopathic formulation of feverfew and ginger that eliminates migraine pain and associated symptoms, is the only recommended first-line therapy for acute migraine in the retail market today that has shown no evidence of rebound or medication-overuse headache.

PuraMed BioScience Inc reports 42.6m outstanding shares in issue
M2 - Wed Jul 03, 4:36AM CDT
Medicinal products company PuraMed BioScience Inc (OTC BB MBS) declared on Tuesday that its current common shares issued and outstanding totalled 42,610,297 as of 30 June 2013.

PuraMed BioScience Announces Common Shares Outstanding of 42.6 Million
PR Newswire - Tue Jul 02, 10:27AM CDT
PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announces update of current share structure.

PuraMed BioScience® Announces Science Behind LipiGesic® M Migraine Treatment
PR Newswire - Fri Jun 21, 10:05AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the science behind LipiGesic® M, its homeopathic, over-the-counter migraine medication.

PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
PR Newswire - Mon Jun 10, 7:00AM CDT
PuraMed BioScience®, Inc., (OTCBB MBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced an interview conducted on Big Biz Show with PuraMed BioScience's CEO Russ Mitchell to discuss and inform listeners about PuraMed BioScience's flagship product, LipiGesic® M.



Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 2

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 1

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 1

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 5

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 1

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 7

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 8

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 3

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 2

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Acumen Pharmaceuticals to Showcase Innovations at Conference

Updated Category News Views 115

Acumen Pharmaceuticals to Present at Health Conference Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a pioneering clinical-stage biopharmaceutical company, is set to engage in a significant fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. This event will happen shortly, providing a platform for Acumen to discuss their innovative approaches to tackling...

Continue Reading
Chanson International Holding Reports Fiscal Year 2025 Mid-Year Results

Updated Category News Views 192

Chanson International Holding Reports Mid-Year Financial Results Chanson International Holding (NASDAQ: CHSN) has recently unveiled its financial performance for the first half of the fiscal year 2025. As a key player in the bakery and beverage sectors, the company's unaudited results signify its resilience in a fluctuating market. Overview of Financial Performance...

Continue Reading
Investors Are Strategically Analyzing REGN Options Activity

Updated Category News Views 66

Examining Recent Changes in REGN Options There's been a noteworthy shift in sentiment among financial experts regarding Regeneron Pharmaceuticals. A recent analysis of the trading patterns in REGN options has revealed a blend of bullish and bearish movements in the market. This information serves as a foundation for understanding the current factors that are shaping...

Continue Reading
Analysts Raise Price Targets for CVS After Strong Earning Report

Updated Category News Views 99

CVS Health Exceeds Expectations with Recent Earnings CVS Health Corp (NYSE: CVS) delivered an impressive earnings report for its fourth quarter, showing robust sales numbers that surpassed analysts' expectations. The company announced fourth-quarter sales totaling an incredible $97.71 billion, outpacing the consensus estimate of $97.19 billion. Adjusted Earnings Report...

Continue Reading
Healthcare Triangle and Teyame AI Join Forces to Innovate Patient Engagement

Updated Category News Views 161

Healthcare Triangle Announces Strategic Partnership with Teyame AI Healthcare Triangle, Inc. (Nasdaq: HCTI) is excited to share its recent agreement with Teyame AI LLC, a visionary corporation aiming to revolutionize customer experience through artificial intelligence. This partnership is a transformative step that will not only enhance HCTI's SaaS capabilities but is...

Continue Reading